How should persistent monocytosis be evaluated and managed?

Evaluation and Management of Persistent Monocytosis

Persistent monocytosis (>1×10⁹/L for >3 months) requires a systematic workup to exclude chronic myelomonocytic leukemia (CMML) and other hematologic malignancies, beginning with exclusion of reactive causes, followed by bone marrow evaluation with cytogenetics and molecular testing if no secondary cause is identified 1.

Initial Diagnostic Approach

Step 1: Confirm True Monocytosis

• Verify absolute monocyte count >1×10⁹/L (newer classifications use ≥0.5×10⁹/L threshold) with manual differential review by an experienced morphologist 1, 2
• Exclude cytological mimics: hairy cells, promonocytes, or monoblasts that can falsely elevate automated counts 3

Step 2: Exclude Reactive Causes

Most monocytosis is secondary and easily identified by clinical context 4. Specifically investigate:

• Infectious diseases: Active or recent infections (bacterial, viral, fungal, mycobacterial)
• Inflammatory conditions: Systemic autoimmune diseases, inflammatory bowel disease
• Solid tumors: Particularly lung, breast, ovarian, and gastrointestinal malignancies
• Hematologic recovery: Post-chemotherapy or growth factor administration
• Medications: Corticosteroids, granulocyte colony-stimulating factors

Look for accompanying inflammatory markers (elevated CRP, ESR) which suggest reactive etiology 1.

Step 3: If No Reactive Cause After 3 Months - Pursue Clonal Workup

The diagnostic workup must include 1:

Blood and Bone Marrow Studies:

• Complete blood count with peripheral smear examination for dysplasia and blast percentage
• Bone marrow aspiration and biopsy with morphologic assessment for dysplasia
• Conventional cytogenetic analysis (abnormalities in ~30% of CMML, most commonly chromosome 7 abnormalities, trisomy 8, complex karyotype) 1

Molecular Exclusions (Critical):

• BCR-ABL1 fusion gene testing to exclude chronic myeloid leukemia 1
• PDGFRA and PDGFRB rearrangement testing if eosinophilia is present (>1.5×10⁹/L) to exclude myeloid/lymphoid neoplasms with eosinophilia 1

Molecular Mutation Analysis:

Targeted sequencing has transformed diagnostic accuracy 5. Test for:

• TET2 (~60% of CMML)
• SRSF2 (~50% of CMML)
• ASXL1 (~40% of CMML)
• RAS pathway genes (NRAS, KRAS) (~30%)
• Additional genes: DNMT3A, CBL, JAK2, RUNX1 6

Critical diagnostic insight: The absence of TET2, SRSF2, or ASXL1 mutations has ≥90% negative predictive value for CMML 7. Conversely, somatic mutations are detected in 79-93% of patients with monocytosis referred for evaluation, and their presence—even without definitive morphologic diagnosis—predicts outcomes identical to confirmed CMML 5.

Flow Cytometry:

While not required by WHO criteria, flow cytometry can support diagnosis by detecting:

• Aberrant monocyte immunophenotype (CD11b/HLA-DR, CD36/CD14 abnormalities)
• Abnormal CD13, CD14, CD16, CD33 expression
• CD56 overexpression (highly specific for detecting mutations) 5
• Monocyte subset repartitioning patterns 2

WHO 2008 Diagnostic Criteria for CMML

CMML diagnosis requires ALL of the following 1:

1. Persistent peripheral blood monocytosis (>1×10⁹/L)
2. No Philadelphia chromosome or BCR-ABL1 fusion gene
3. No PDGFRA or PDGFRB rearrangement (must exclude if eosinophilia present)
4. <20% blasts in peripheral blood and bone marrow (includes myeloblasts, monoblasts, promonocytes)
5. At least ONE of:
   • Dysplasia in ≥1 cell lineage, OR
   • Acquired clonal cytogenetic/molecular abnormality in hematopoietic cells, OR
   • Persistence of monocytosis ≥3 months with no other identifiable cause

Management Based on Classification

Classify Disease Phenotype:

• Myelodysplastic-type (MD-CMML): WBC <13×10⁹/L
• Myeloproliferative-type (MP-CMML): WBC ≥13×10⁹/L 1

Treatment Algorithm:

MD-CMML with <10% bone marrow blasts 1:

• Supportive care for cytopenias
• Erythropoiesis-stimulating agents if Hb ≤10 g/dL and serum EPO ≤500 mU/dL
• Myeloid growth factors only for febrile severe neutropenia

MD-CMML with ≥10% bone marrow blasts or ≥5% peripheral blasts 1:

• Hypomethylating agents (5-azacytidine or decitabine) plus supportive care
• Consider allogeneic stem cell transplant (ASCT) in selected patients within clinical trials

MP-CMML with <10% blasts 1:

• Hydroxyurea as first-line cytoreductive therapy to control proliferation and reduce organomegaly

MP-CMML with high blast count 1:

• Polychemotherapy followed by ASCT when feasible
• If ASCT not possible, chemotherapy recommended to maintain quality of life despite non-curative intent

Risk Stratification:

Use Mayo Molecular Model (MMM) for prognostication 6:

• High risk (≥3 factors): median survival 16 months
• Intermediate-2 (2 factors): 31 months
• Intermediate-1 (1 factor): 59 months
• Low risk (0 factors): 97 months

Risk factors: truncating ASXL1 mutations, absolute monocyte count >10×10⁹/L, Hb <10 g/dL, platelets <100×10⁹/L, circulating immature myeloid cells.

Critical Pitfalls to Avoid

1. Don't dismiss persistent monocytosis as reactive without thorough investigation - 57% of patients without diagnostic bone marrow features but with somatic mutations have outcomes identical to confirmed CMML 5

2. Don't delay molecular testing - Patients with mutations but "borderline" morphology should be managed as CMML given identical survival outcomes 5

3. Monitor renal function in proliferative disease - Lysozyme-induced nephropathy can occur during leukocytosis and may require cytoreductive therapy 6

4. HLA typing should be performed in patients <65 years at diagnosis, as ASCT is the only curative option 1

5. Re-evaluate patients starting therapy >3 months from diagnosis with repeat bone marrow, cytogenetics, and clinical assessment 1